Andrea Kassai1, Ranganath Muniyappa1, Amy E Levenson1, Mary F Walter1, Brent S Abel1, Michael Ring1, Simeon I Taylor1, Sudha B Biddinger1, Monica C Skarulis1, Phillip Gorden1, Rebecca J Brown1. 1. Diabetes, Endocrinology and Obesity Branch (A.K., R.M., B.S.A., M.R., M.C.S., P.G., R.J.B.), Clinical Core Laboratory (M.F.W.), National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892; Division of Endocrinology (A.E.L., S.B.B.), Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115; and Division of Endocrinology, Diabetes, and Nutrition (S.I.T.), University of Maryland School of Medicine, Baltimore, Maryland 21201.
Abstract
CONTEXT: Apolipoprotein CIII (apoCIII), an inhibitor of lipoprotein lipase, plays an important role in triglyceride metabolism. However, the role of apoCIII in hypertriglyceridemia in lipodystrophy and the effects of leptin replacement on apoCIII levels are unknown. OBJECTIVE: The objective of the study was to test the hypotheses that apoCIII is elevated in hypertriglyceridemic patients with lipodystrophy and that leptin replacement in these patients lowers circulating apoCIII. DESIGN, SETTING, STUDY PARTICIPANTS, INTERVENTION, AND OUTCOME MEASURES: Using a post hoc cross-sectional case-control design, we compared serum apoCIII levels from patients with lipodystrophy not associated with HIV (n = 60) and age-, gender-, race-, and ethnicity-matched controls (n = 54) participating in ongoing studies at the National Institutes of Health. In a prospective, open-label, ongoing study, we studied the effects of 6–12 months of leptin replacement on apoCIII in lipodystrophy patients as an exploratory outcome. RESULTS: ApoCIII was higher in lipodystrophy patients (geometric mean [25th and 75th percentiles]) (23.9 mg/dL [14.6, 40.3]) compared with controls (14.9 mg/dL [12.3, 17.7]) (P < .0001). ApoCIII and triglyceride levels were positively correlated in patients with lipodystrophy (R = 0.72, P < .0001) and healthy controls (R = 0.6, P < .0001). Leptin replacement (6–12 mo) did not significantly alter apoCIII (before leptin: 23.4 mg/dL [14.5, 40.1]; after leptin: 21.4 mg/dL [16.7, 28.3]; P = .34). CONCLUSIONS: Leptin replacement in lipodystrophy did not alter serum apoCIII levels. Elevated apoCIII may play a role in the hypertriglyceridemia of lipodystrophy independent of leptin deficiency and replacement.
CONTEXT: Apolipoprotein CIII (apoCIII), an inhibitor of lipoprotein lipase, plays an important role in triglyceride metabolism. However, the role of apoCIII in hypertriglyceridemia in lipodystrophy and the effects of leptin replacement on apoCIII levels are unknown. OBJECTIVE: The objective of the study was to test the hypotheses that apoCIII is elevated in hypertriglyceridemicpatients with lipodystrophy and that leptin replacement in these patients lowers circulating apoCIII. DESIGN, SETTING, STUDY PARTICIPANTS, INTERVENTION, AND OUTCOME MEASURES: Using a post hoc cross-sectional case-control design, we compared serum apoCIII levels from patients with lipodystrophy not associated with HIV (n = 60) and age-, gender-, race-, and ethnicity-matched controls (n = 54) participating in ongoing studies at the National Institutes of Health. In a prospective, open-label, ongoing study, we studied the effects of 6–12 months of leptin replacement on apoCIII in lipodystrophypatients as an exploratory outcome. RESULTS:ApoCIII was higher in lipodystrophypatients (geometric mean [25th and 75th percentiles]) (23.9 mg/dL [14.6, 40.3]) compared with controls (14.9 mg/dL [12.3, 17.7]) (P < .0001). ApoCIII and triglyceride levels were positively correlated in patients with lipodystrophy (R = 0.72, P < .0001) and healthy controls (R = 0.6, P < .0001). Leptin replacement (6–12 mo) did not significantly alter apoCIII (before leptin: 23.4 mg/dL [14.5, 40.1]; after leptin: 21.4 mg/dL [16.7, 28.3]; P = .34). CONCLUSIONS:Leptin replacement in lipodystrophy did not alter serum apoCIII levels. Elevated apoCIII may play a role in the hypertriglyceridemia of lipodystrophy independent of leptin deficiency and replacement.
Authors: Kazunori Nagashima; Carlos Lopez; Daniel Donovan; Colleen Ngai; Nelson Fontanez; André Bensadoun; Jamila Fruchart-Najib; Steve Holleran; Jeffrey S Cohn; Rajasekhar Ramakrishnan; Henry N Ginsberg Journal: J Clin Invest Date: 2005-04-01 Impact factor: 14.808
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Ranganath Muniyappa; Brent S Abel; Asha Asthana; Mary F Walter; Elaine K Cochran; Alan T Remaley; Monica C Skarulis; Phillip Gorden; Rebecca J Brown Journal: J Clin Lipidol Date: 2017-02-24 Impact factor: 4.766
Authors: Marissa Lightbourne; Anna Wolska; Brent S Abel; Kristina I Rother; Mary Walter; Yevgeniya Kushchayeva; Sungyoung Auh; Robert D Shamburek; Alan T Remaley; Ranganath Muniyappa; Rebecca J Brown Journal: J Endocr Soc Date: 2020-12-04